1-5 of 5
Jae-Weon Kim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial

Junsik Park, Je-Gun Joung, Myong Cheol Lim, Jungbok Lee, Byoung-Gie Kim, Jae-Weon Kim, So Jin Shin, Sunghoon Kim, Eunhyang Park, Chel Hun Choi, Hee Seung Kim, Sang Yoon Park, Jung-Yun Lee
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF12.
https://doi.org/10.1158/1078-0432.CCR-24-3753
Published: 28 March 2025
View articletitled, Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial
Open the PDF for Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae-Weon Kim, Richard T. Penson, David M. O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja De Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee, for the MEDIOLA Investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 50–62.
https://doi.org/10.1158/1078-0432.CCR-23-2249
Published: 05 January 2024
View articletitled, Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Open the PDF for Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study in another window
Includes: Supplementary data
Journal Articles

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Nicola S. Meagher, Kylie L. Gorringe, Matthew Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S. Chiu, Michael S. Anglesio, Kylie-Ann Mallitt, Jennifer A. Doherty, Holly R. Harris, Joellen M. Schildkraut, Andrew Berchuck, Kara L. Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W. Beckmann, Jessica Boros, David D.L. Bowtell, for the AOCS Group, Alison H. Brand, James D. Brenton, Ian Campbell, Dane Cheasley, Joshua Cohen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Rhonda Farrell, Anna Fischer, Zhuxuan Fu, Blake Gilks, Anthony J. Gill, for the Australian Pancreatic Genome Initiative, Charlie Gourley, Marcel Grube, Paul R. Harnett, Arndt Hartmann, Anusha Hettiaratchi, Claus K. Høgdall, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J. Kennedy, Byoung-Gie Kim, Jae-Weon Kim, Jae-Hoon Kim, Kayla Klett, Jennifer M. Koziak, Tiffany Lai, Angela Laslavic, Jenny Lester, Yee Leung, Na Li, Winston Liauw, Belle W.X. Lim, Anna Linder, Jan Lubiński, Sakshi Mahale, Constantina Mateoiu, Simone McInerny, Janusz Menkiszak, Parham Minoo, Suzana Mittelstadt, David Morris, Sandra Orsulic, Sang-Yoon Park, Celeste Leigh Pearce, John V. Pearson, Malcolm C. Pike, Carmel M. Quinn, Ganendra Raj Mohan, Jianyu Rao, Marjorie J. Riggan, Matthias Ruebner, Stuart Salfinger, Clare L. Scott, Mitul Shah, Helen Steed, Colin J.R. Stewart, Deepak Subramanian, Soseul Sung, Katrina Tang, Paul Timpson, Robyn L. Ward, Rebekka Wiedenhoefer, Heather Thorne, for the kConFab Investigators, Paul A. Cohen, Philip Crowe, Peter A. Fasching, Jacek Gronwald, Nicholas J. Hawkins, Estrid Høgdall, David G. Huntsman, Paul A. James, Beth Y. Karlan, Linda E. Kelemen, Stefan Kommoss, Gottfried E. Konecny, Francesmary Modugno, Sue K. Park, Annette Staebler, Karin Sundfeldt, Anna H. Wu, Aline Talhouk, Paul D.P. Pharoah, Lyndal Anderson, Anna DeFazio, Martin Köbel, Michael L. Friedlander, Susan J. Ramus
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5383–5395.
https://doi.org/10.1158/1078-0432.CCR-22-1206
Published: 15 December 2022
View articletitled, Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
Open the PDF for Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes in another window
Includes: Supplementary data
Journal Articles

Clinical significance of the mTOR pathway in epithelial ovarian cancer

Jae Hong No, In-Ae Park, Jae Weon Kim, Noh-Hyun Park, Soon-Beom Kang, Heebal Kim, Jeong Mook Lim, Jae Yong Han, Yong-Sang Song
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (19_Supplement): A29.
Published: 15 August 2014
View articletitled, Clinical significance of the mTOR pathway in epithelial ovarian cancer
Journal Articles

Polymorphisms of ERCC1 C8092A and glutathione-S-transferase T1 (GSTT1) associated with survival and response after platinum-based chemotherapy in patients with epithelial ovarian cancer

Hee Seung Kim, Jae Weon Kim, Soon-Beom Kang
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): A54.
Published: 15 August 2014
View articletitled, Polymorphisms of ERCC1 C8092A and glutathione-S-transferase T1 (GSTT1) associated with survival and response after platinum-based chemotherapy in patients with epithelial ovarian cancer